Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tacrolimus

FDA-approved product (capsule, oral), marketed as Astagraf Xl, Envarsus Xr, Prograf and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tacrolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Delayed Graft Function
  • Eczematoid dermatitis
  • Immune system disease
  • Kidney transplant
  • Liver transplant

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids; Calcineurin inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tacrolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tacrolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Islet Allotransplantation for Type 1 Diabetic Patients

    NCT03259256 · start 2017-04-23

    Registered record
    Registry ID
    NCT03259256
    Conditions
    Type 1 Diabetic
    Interventions
    Allogeneic transplantation of intrahepatic islet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-04-23
    Completion
    2019-06-30
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetic
    InterventionAllogeneic transplantation of intrahepatic islet
    PhasePhase 3
    Registry statusUnknown

  • Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association

    NCT03228576 · start 2017-04-14

    Registered record
    Registry ID
    NCT03228576
    Conditions
    Kidney Transplant; Immunosuppression
    Interventions
    Extended release Tacrolimus-Everolimus association
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2017-04-14
    Completion
    2018-12-18
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant; Immunosuppression
    InterventionExtended release Tacrolimus-Everolimus association
    PhaseNot recorded
    Registry statusTerminated

  • Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

    NCT03478215 · start 2016-12

    Registered record
    Registry ID
    NCT03478215
    Conditions
    Renal Transplantation; Mesenchymal Stem Cells
    Interventions
    Mesenchymal Stromal Stem Cells (MSCs) Infusion; Normal Saline (Placebo) Infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-12
    Completion
    2026-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplantation; Mesenchymal Stem Cells
    InterventionMesenchymal Stromal Stem Cells (MSCs) Infusion; Normal Saline (Placebo) Infusion
    PhasePhase 2
    Registry statusActive not recruiting

  • PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)

    NCT02882828 · start 2016-10

    Registered record
    Registry ID
    NCT02882828
    Conditions
    Allograft
    Interventions
    switched from Prograf® to Envarsus®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10
    Completion
    2020-03
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllograft
    Interventionswitched from Prograf® to Envarsus®
    PhasePhase 4
    Registry statusCompleted

  • Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center

    NCT02409147 · start 2016-01

    Registered record
    Registry ID
    NCT02409147
    Conditions
    Uterus Transplant
    Interventions
    Uterine Transplant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2016-01
    Completion
    2018-07-24
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterus Transplant
    InterventionUterine Transplant
    PhaseNot applicable
    Registry statusWithdrawn

  • PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

    NCT02584647 · start 2015-11-04

    Registered record
    Registry ID
    NCT02584647
    Conditions
    Sarcoma; Malignant Peripheral Nerve Sheath Tumors
    Interventions
    PLX3397; sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-11-04
    Completion
    2024-10-01
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma; Malignant Peripheral Nerve Sheath Tumors
    InterventionPLX3397; sirolimus
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    NCT02356159 · start 2015-09-24

    Registered record
    Registry ID
    NCT02356159
    Conditions
    Myelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia; Multiple Myeloma
    Interventions
    Rituximab; Conditioning chemotherapy; TMS; FLAG; EPOCH-F; Hematopoietic stem cell transplant; Palifermin; Acetaminophen; Diphenhydramine; Prednisone; Epinephrine; IV Saline; ECG; ECHO; MUGA; DEXA; CT chest; PET; MRI; BM aspirate; BM biopsy; Lumbar puncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-09-24
    Completion
    2025-03-25
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia +1 more
    InterventionRituximab; Conditioning chemotherapy; TMS; FLAG +18 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

    NCT02199041 · start 2014-07-11

    Registered record
    Registry ID
    NCT02199041
    Conditions
    Hematological Malignancies
    Interventions
    Cyclophosphamide; Thiotepa; Fludarabine; Melphalan; Mesna; G-CSF; Mycophenolate mofetil; Tacrolimus; Methylprednisolone; Total lymphoid irradiation; Lymphocyte infusions; CliniMACS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-07-11
    Completion
    2017-05-23
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancies
    InterventionCyclophosphamide; Thiotepa; Fludarabine; Melphalan +8 more
    PhasePhase 2
    Registry statusTerminated

  • A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.

    NCT02040584 · start 2013-12-20

    Registered record
    Registry ID
    NCT02040584
    Conditions
    Liver Transplant
    Interventions
    Minimisation of TAC; TAC + MMF + corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12-20
    Completion
    2016-02-10
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant
    InterventionMinimisation of TAC; TAC + MMF + corticosteroids
    PhasePhase 3
    Registry statusCompleted

  • Simulect Versus ATG in Sensitized Renal Transplant Patient

    NCT02377193 · start 2013-09

    Registered record
    Registry ID
    NCT02377193
    Conditions
    Renal Transplant Rejection
    Interventions
    Simulect; ATG Fresenius
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09
    Completion
    2017-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplant Rejection
    InterventionSimulect; ATG Fresenius
    PhasePhase 4
    Registry statusCompleted

  • A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

    NCT01878786 · start 2013-06

    Registered record
    Registry ID
    NCT01878786
    Conditions
    Delayed Graft Function
    Interventions
    Everolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2017-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Graft Function
    InterventionEverolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • PEL-1235_REN-0176-I (Pelicon)

    NCT01904045 · start 2013-05

    Registered record
    Registry ID
    NCT01904045
    Conditions
    Immunosuppression After Kidney Transplantation
    Interventions
    tacrolimus Advagraf; tacrolimus Prograf
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-05
    Completion
    2018-08
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmunosuppression After Kidney Transplantation
    Interventiontacrolimus Advagraf; tacrolimus Prograf
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients

    NCT01316133 · start 2011-04-19

    Registered record
    Registry ID
    NCT01316133
    Conditions
    Lupus Nephritis
    Interventions
    tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-04-19
    Completion
    2016-04-08
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    Interventiontacrolimus
    PhasePhase 4
    Registry statusTerminated

  • Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

    NCT01154387 · start 2010-07

    Registered record
    Registry ID
    NCT01154387
    Conditions
    End Stage Renal Disease; Renal Transplant
    Interventions
    Anti-Thymocyte Globulin; TOL101; TOL101; Steroids; Tacrolimus; Mycophenolate mofetil (MMF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2013-06
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Renal Transplant
    InterventionAnti-Thymocyte Globulin; TOL101; TOL101; Steroids +2 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

    NCT01150097 · start 2010-03-31

    Registered record
    Registry ID
    NCT01150097
    Conditions
    Liver Transplant Recipient
    Interventions
    Tacrolimus (reduced tacrolimus); Everolimus (reduced tacrolimus); Tacrolimus (tacrolimus elimination); Everolimus (tacrolimus elimination); Tacrolimus (tacrolimus control); Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03-31
    Completion
    2013-05-03
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant Recipient
    InterventionTacrolimus (reduced tacrolimus); Everolimus (reduced tacrolimus); Tacrolimus (tacrolimus elimination); Everolimus (tacrolimus elimination) +2 more
    PhasePhase 3
    Registry statusCompleted